Emmaus Life Sciences (OTCMKTS:EMMA) Stock Price Breaks Below 200 Day Moving Average – Time to Sell?

Shares of Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) crossed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $0.02 and traded as low as $0.0150. Emmaus Life Sciences shares last traded at $0.0150, with a volume of 26,978 shares.

Emmaus Life Sciences Trading Down 31.5%

The company has a 50 day simple moving average of $0.05 and a two-hundred day simple moving average of $0.02. The firm has a market capitalization of $1.05 million, a P/E ratio of -0.17 and a beta of 11.25.

Emmaus Life Sciences (OTCMKTS:EMMA) last released its quarterly earnings data on Friday, August 14th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $6.32 million for the quarter.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and debilitating diseases. The company’s best-known product is Endari, an oral powder formulation of L-glutamine approved in the United States to reduce the frequency of acute complications associated with sickle cell disease in adults and children aged five and older. Emmaus has focused its research and development activities on therapies for diseases with significant unmet medical needs, including hematological and other rare disorders.